{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134758","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.194466+00:00","generated_at":"2026-06-02T06:42:20.513369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Royalty Pharma Q1 Royalty Receipts +14% to $705M; FY2024 guidance reaffirmed","bullets":["Portfolio Receipts of $717M, down 37% from $1,131M YoY due to $475M Biohaven milestone in Q1 2023.","Royalty Receipts grew 14% to $705M, led by Evrysdi, Trelegy, and the cystic fibrosis franchise.","Full-year 2024 Portfolio Receipts guidance reaffirmed at $2.6B–$2.7B, with Royalty Receipts growth of 5%–9%.","Announced ~$525M acquisition of royalties on Sanofi’s frexalimab (Phase 3 multiple sclerosis); $5.9B total liquidity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134758","json":"https://secwatch.observer/filing/0001193125-24-134758.json","markdown":"https://secwatch.observer/filing/0001193125-24-134758.md","text":"https://secwatch.observer/filing/0001193125-24-134758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/0001193125-24-134758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/d834416d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:42:20.513369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"200642edf32fef401afbce50af8656d21da4d6a6","claim":"Royalty Pharma plc updated its first quarter of 2024 guidance (reaffirmed).","evidence_excerpt":"On May 9, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/0001193125-24-134758-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}